Eli Lilly lowers FY2026 adjusted EPS guidance, raises sales guidance

Eli Lilly lowered its FY2026 adjusted EPS guidance from $35.50-$36.50 to $35.00-$36.00, versus the $34.04 estimate, and raised FY2026 sales guidance from $85.000B-$87.000B to $91.000B-$92.000B, versus the $88.848B estimate.

Detected & updated continuously · Source: Nebula